Investigating the rate of prevalence of early-stage breast cancer in comparison with other stages breast cancer


Ziba Heidarpoor, Seyed Hesam Addin Bani Hashemi


Background: Breast cancer is the most common type of cancer among Iranian women. In 70% of patients, the disease reaches an advanced stage when discovered. 30% of cases are discovered when the disease has not reached to the stage, but the size is over 5 cm. Five-year survival rate of this disease in Iran is about 62% which is slightly more than other nations. Patients suffering from the disease experience reduced quality of life due to their physical and psychological complications. Accordingly, timely diagnosis of the disease and its proper treatment are among the things that can significantly reduce the death rate of the disease. However, the stage of the disease at which patients refer to doctor is a topic that has not been investigated so far on Iranian patients. Therefore, we decided in this study to investigate the prevalence of Early stage breast cancer in comparison with other breast cancer staging in Bu-Ali, Jam, and Mehr hospitals during the years 2006 to 2011.

Method: The study population included 167 women admitted in Bu-Ali, Jam, and Mehr hospitals from 2006 to 2011. Finally, after collecting the required data, it was analyzed using SPSS 19 software.

Results: There was no significant relationship between estrogen, progesterone and HER-2neu receptors with breast cancer stage, place of involvement and type of cancer, but there was a significant relationship between estrogen and progesterone with BMI.

Conclusion: In patients with negative estrogen, progesterone, and HER-2neu, there was no significant correlation between these receptors and the stage of cancer.


Breast cancer, Early stage, Estrogen, Progesterone

  1. Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A, Breast cancer in Iran: a review of 903 cases records, Public Health, 2000, 114(2): 143-5.

  2. Vahdaninia M, Montazeri A, Breast cancer in Iran: a survival analysis Asian Pac j cancer Prev, 2004, 5(2): 223-5.

  3. Radice D, Redaelli A, Breast cancer management: quality-of-life and cost considerations, pharmacoeconomics, 2003, 21(6): 383-96.

  4. Showartz, Principles of surgery , 2010, Mc – Grow Hill publisher

  5. Mass HB, Berry DA, Cirrincione CT, Adjuvant chemotherapy in older women with early-stage breast cancer, N Engl J Med, 2009, 360(20): 2055-6

  6. Patridge AH, Archer L, Kornblith AB, Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CA1GB 49907: adherence companion study 60104, J clin oncol, 2010, 28(14): 2418-22.

  7. Adjuvant Breast Cancer Trials Collaborative Group, polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial, J Natl Cancer Ins, 2007, 99(7): 506-15.

  8. Ebrahimi M, Vahdaninia M, Montazeri A, Risk factors for breast cancer in Iran: a case-control study, Breast cancer Res, 2002, 4(5): R10.

  9. Single tary SE, Rating the risk factors for breast cancer, Ann surg, 2003, 237(4): 474-82.

  10. Simes RJ, Coates AS, Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?  J Natl Cancer Ins, 2001, 30: 146-52.